RECURRENT HEPATOCELLULAR CARCINOMA
Clinical trials for RECURRENT HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Proton beams vs X-Rays: which is better for liver cancer?
Disease control OngoingThis phase III trial tests whether proton radiation therapy works better than standard photon (X-ray) radiation for people with liver cancer that cannot be removed by surgery or has come back. The study involves 115 participants and compares overall survival and side effects. Pro…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental combo aims to rally immune system against tough liver cancer
Disease control OngoingThis early-phase trial tests whether adding an immune-boosting drug called IRX-2 to standard immunotherapy (nivolumab) and a low dose of chemotherapy (cyclophosphamide) is safe and tolerable for people with advanced liver cancer that has come back or spread. Only 8 participants a…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC